Evogliptin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Evogliptin
Accession Number
DB12625
Type
Small Molecule
Groups
Investigational
Description

Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

Structure
Thumb
Synonyms
Not Available
External IDs
DA-1229
Categories
UNII
09118300L7
CAS number
1222102-29-5
Weight
Average: 401.43
Monoisotopic: 401.192626198
Chemical Formula
C19H26F3N3O3
InChI Key
LCDDAGSJHKEABN-MLGOLLRUSA-N
InChI
InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
IUPAC Name
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(tert-butoxy)methyl]piperazin-2-one
SMILES
CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Evogliptin.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Evogliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Evogliptin.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Evogliptin.
AcetazolamideThe therapeutic efficacy of Evogliptin can be increased when used in combination with Acetazolamide.
AcetohexamideEvogliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Evogliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Evogliptin.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Evogliptin.
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Evogliptin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25022354
PubChem Substance
347828837
ChemSpider
26339341
BindingDB
50344779
ChEMBL
CHEMBL1779710
HET
8VU
Wikipedia
Evogliptin
ATC Codes
A10BH07 — EvogliptinA10BD22 — Metformin and evogliptin
PDB Entries
5y7k

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableImpaired Renal Function1
1CompletedTreatmentLiver Dysfunction1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Unknown StatusScreeningHealthy Volunteers1
1Unknown StatusTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus1
2Enrolling by InvitationTreatmentAlbuminuria / Impaired Renal Function / Type2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus2
4CompletedTreatmentType2 Diabetes1
4Not Yet RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Type2 Diabetes1
4RecruitingTreatmentOsteoporosis / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP1.29ALOGPS
logP1.17ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)13.69ChemAxon
pKa (Strongest Basic)8.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.66 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.43 m3·mol-1ChemAxon
Polarizability39.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Hybrid peptides
Direct Parent
Hybrid peptides
Alternative Parents
Beta amino acids and derivatives / Alpha amino acids and derivatives / Amphetamines and derivatives / Aralkylamines / Fluorobenzenes / Piperazines / Aryl fluorides / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams
show 8 more
Substituents
Hybrid peptide / Beta amino acid or derivatives / Alpha-amino acid or derivatives / Amphetamine or derivatives / Aralkylamine / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Monocyclic benzene moiety
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:18 / Updated on June 04, 2019 07:40